Exact Mass: 1086.3885

Exact Mass Matches: 1086.3885

Found 22 metabolites which its exact mass value is equals to given mass value 1086.3885, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Triostin A

N-[(1R,4S,7R,11S,14R,17S,20R,24S)-2,4,12,15,17,25-hexamethyl-3,6,10,13,16,19,23,26-octaoxo-11,24-di(propan-2-yl)-20-(quinoxaline-2-carbonylamino)-9,22-dioxa-28,29-dithia-2,5,12,15,18,25-hexazabicyclo[12.12.4]triacontan-7-yl]quinoxaline-2-carboxamide

C50H62N12O12S2 (1086.4051)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents

   

Hexaglutamyl folate

(2S,7R,11S)-2,11-Diamino-6-[(4S)-4-amino-4-carboxybutanoyl]-7-{n-[(4S)-4-amino-4-carboxybutanoyl]-1-(4-{[(4-hydroxy-2-imino-1,2-dihydropteridin-6-yl)methyl]amino}phenyl)formamido}-7-({[(4S)-4-amino-4-carboxybutanoyl]oxy}carbonyl)-6-(carboxymethyl)-5,8-dioxododecanedioate

C44H54N12O21 (1086.3526)


Hexaglutamyl folate is a naturally occurring form of folic acid. The bioavailability of dietary folate may be hampered by the need of the glutamate moieties to be deconjugated before absorption. Folate deficiency in humans leads to anemia, neural tube defects and, possibly, chronic diseases such as cardiovascular disease, colon cancer, and neurocognitive dysfunction. Folate status is ascertained not only by the intake of folate but also by its bioavailability. Bioavailability is defined as the proportion of ingested folate that is absorbed and available for metabolic processes and storage. In humans, the bioavailability of folate from the diet is assumed to be {approx}50\\%, whereas the bioavailability of synthetic folic acid used in supplements and as a food fortificant is estimated to range from 76\\% to 97\\%. (PMID: 17093166). Patients with pernicious anemia in relapse and postgastrectomy macrocytic anemia cannot readily utilize for hematopoiesis a naturally occurring conjugate of pteroylglutamic acid although they respond promptly to administration of the free vitamin. This effect varies in different patients. Inability to utilize the conjugated vitamin appears to depend at least in part upon a conjugase-inhibiting substance present in natural sources of conjugate. (PMID: 1082804). Hexaglutamyl folate is a naturally occurring form of folic acid. The bioavailability of dietary folate may be hampered by the need of the glutamate moieties to be deconjugated before absorption. Folate deficiency in humans leads to anemia, neural tube defects and, possibly, chronic diseases such as cardiovascular disease, colon cancer, and neurocognitive dysfunction. Folate status is ascertained not only by the intake of folate but also by its bioavailability. Bioavailability is defined as the proportion of ingested folate that is absorbed and available for metabolic processes and storage. In humans, the bioavailability of folate from the diet is assumed to be {approx}50\\%, whereas the bioavailability of synthetic folic acid used in supplements and as a food fortificant is estimated to range from 76\\% to 97\\%. (PMID: 17093166)

   

Hexaglutamyl folate (THF)

(2R,7R,11R)-2,11-diamino-6-[(4R)-4-amino-4-carboxybutanoyl]-7-{N-[(4R)-4-amino-4-carboxybutanoyl]-1-(4-{[(4-hydroxy-2-imino-1,2-dihydropteridin-6-yl)methyl]amino}phenyl)formamido}-7-({[(4R)-4-amino-4-carboxybutanoyl]oxy}carbonyl)-6-(carboxymethyl)-5,8-dioxododecanedioic acid

C44H54N12O21 (1086.3526)


This compound belongs to the family of Pteroic Acids and Derivatives. These are compounds that are composed of a pterin with a 4-aminobenzoic acid (or derviative) at the 6 position on the pteridine ring.

   

epioritin-(4beta->3)-epioritin-(4beta->6)-epioritin-4beta-ol nona-O-methylether triacetate

epioritin-(4beta->3)-epioritin-(4beta->6)-epioritin-4beta-ol nona-O-methylether triacetate

C60H62O19 (1086.3885)


   
   

epioritin-(4beta->6)-epioritin-(4alpha->4)-epioritin-4beta-ol nona-O-methylether triacetate

epioritin-(4beta->6)-epioritin-(4alpha->4)-epioritin-4beta-ol nona-O-methylether triacetate

C60H62O19 (1086.3885)


   

Pteglu6

N-[N-[N-[N-[N-[N-[4-[[(2-amino-1,4-dihydro-4-oxo-6-Pteridinyl)methyl]amino]benzoyl]-L-gamma-glutamyl]-L-gamma-glutamyl]-L-gamma-glutamyl]-L-gamma-glutamyl]-L-gamma-glutamyl]-L-glutamic acid

C44H54N12O21 (1086.3526)


   
   

Hexaglutamyl folate (THF)

Hexaglutamyl folate (THF)

C44H54N12O21 (1086.3526)


   

N-[(1R,4S,7R,11S,14R,17S,20R,24S)-2,4,12,15,17,25-hexamethyl-3,6,10,13,16,19,23,26-octaoxo-11,24-di(propan-2-yl)-20-(quinoxaline-2-carbonylamino)-9,22-dioxa-28,29-dithia-2,5,12,15,18,25-hexazabicyclo[12.12.4]triacontan-7-yl]quinoxaline-2-carboxamide

N-[(1R,4S,7R,11S,14R,17S,20R,24S)-2,4,12,15,17,25-hexamethyl-3,6,10,13,16,19,23,26-octaoxo-11,24-di(propan-2-yl)-20-(quinoxaline-2-carbonylamino)-9,22-dioxa-28,29-dithia-2,5,12,15,18,25-hexazabicyclo[12.12.4]triacontan-7-yl]quinoxaline-2-carboxamide

C50H62N12O12S2 (1086.4051)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents

   

GlcA(b1-3)Gal(b1-4)GlcNAc(b1-3)GalNAc(b1-3)Gal(b1-4)b-Glc

GlcA(b1-3)Gal(b1-4)GlcNAc(b1-3)GalNAc(b1-3)Gal(b1-4)b-Glc

C40H66N2O32 (1086.3599)


   

NeuAc(a2-3)Gal(b1-3)[NeuAc(a2-6)]Gal(b1-4)b-Glc

NeuAc(a2-3)Gal(b1-3)[NeuAc(a2-6)]Gal(b1-4)b-Glc

C40H66N2O32 (1086.3599)


   

(2S,4S,5R,6R)-5-acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-6-[(3R,4S,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid

(2S,4S,5R,6R)-5-acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-6-[(3R,4S,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid

C40H66N2O32 (1086.3599)


   

4-{[3-(acetyloxy)-6-[3-(acetyloxy)-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-4-yl]-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-4-yl]oxy}-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-3-yl acetate

4-{[3-(acetyloxy)-6-[3-(acetyloxy)-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-4-yl]-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-4-yl]oxy}-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-3-yl acetate

C60H62O19 (1086.3885)


   

(2r,3r,4s)-4-{[(2r,3r,4r)-3-(acetyloxy)-6-[(2r,3r,4r)-3-(acetyloxy)-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-4-yl]-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-4-yl]oxy}-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-3-yl acetate

(2r,3r,4s)-4-{[(2r,3r,4r)-3-(acetyloxy)-6-[(2r,3r,4r)-3-(acetyloxy)-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-4-yl]-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-4-yl]oxy}-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-3-yl acetate

C60H62O19 (1086.3885)


   

n-(6,19-dihydroxy-20-{[hydroxy(quinoxalin-2-yl)methylidene]amino}-11,24-diisopropyl-2,4,12,15,17,25-hexamethyl-3,10,13,16,23,26-hexaoxo-9,22-dioxa-28,29-dithia-2,5,12,15,18,25-hexaazabicyclo[12.12.4]triaconta-5,18-dien-7-yl)quinoxaline-2-carboximidic acid

n-(6,19-dihydroxy-20-{[hydroxy(quinoxalin-2-yl)methylidene]amino}-11,24-diisopropyl-2,4,12,15,17,25-hexamethyl-3,10,13,16,23,26-hexaoxo-9,22-dioxa-28,29-dithia-2,5,12,15,18,25-hexaazabicyclo[12.12.4]triaconta-5,18-dien-7-yl)quinoxaline-2-carboximidic acid

C50H62N12O12S2 (1086.4051)


   

4-({4-[3,4-bis(acetyloxy)-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-6-yl]-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-3-yl}oxy)-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-3-yl acetate

4-({4-[3,4-bis(acetyloxy)-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-6-yl]-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-3-yl}oxy)-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-3-yl acetate

C60H62O19 (1086.3885)


   

(2r,3s,4s)-3-(acetyloxy)-6-[(2r,3r,4r)-3-{[(2r,3r,4s)-3-(acetyloxy)-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-4-yl]oxy}-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-4-yl]-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-4-yl acetate

(2r,3s,4s)-3-(acetyloxy)-6-[(2r,3r,4r)-3-{[(2r,3r,4s)-3-(acetyloxy)-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-4-yl]oxy}-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-4-yl]-7,8-dimethoxy-2-(4-methoxyphenyl)-3,4-dihydro-2h-1-benzopyran-4-yl acetate

C60H62O19 (1086.3885)


   

7-[(7-{[7-(hydroxymethyl)-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carbonyloxy]methyl}-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carbonyloxy)methyl]-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carboxylic acid

7-[(7-{[7-(hydroxymethyl)-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carbonyloxy]methyl}-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carbonyloxy)methyl]-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carboxylic acid

C48H62O28 (1086.3427)


   

n-[(1s,4s,7r,11s,14s,17s,20r,24s)-6,19-dihydroxy-20-{[hydroxy(quinoxalin-2-yl)methylidene]amino}-11,24-diisopropyl-2,4,12,15,17,25-hexamethyl-3,10,13,16,23,26-hexaoxo-9,22-dioxa-28,29-dithia-2,5,12,15,18,25-hexaazabicyclo[12.12.4]triaconta-5,18-dien-7-yl]quinoxaline-2-carboximidic acid

n-[(1s,4s,7r,11s,14s,17s,20r,24s)-6,19-dihydroxy-20-{[hydroxy(quinoxalin-2-yl)methylidene]amino}-11,24-diisopropyl-2,4,12,15,17,25-hexamethyl-3,10,13,16,23,26-hexaoxo-9,22-dioxa-28,29-dithia-2,5,12,15,18,25-hexaazabicyclo[12.12.4]triaconta-5,18-dien-7-yl]quinoxaline-2-carboximidic acid

C50H62N12O12S2 (1086.4051)


   

(1s,4as,7as)-7-{[(1s,4as,7as)-7-{[(1s,4as,7as)-7-(hydroxymethyl)-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carbonyloxy]methyl}-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carbonyloxy]methyl}-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carboxylic acid

(1s,4as,7as)-7-{[(1s,4as,7as)-7-{[(1s,4as,7as)-7-(hydroxymethyl)-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carbonyloxy]methyl}-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carbonyloxy]methyl}-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carboxylic acid

C48H62O28 (1086.3427)